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OBJECTIVE: The prognostic value of inflammation indexes in esophageal cancer was not established. In this study,
therefore, both prognostic values of Glasgow prognostic score (GPS) and combination of platelet count and
neutrophil lymphocyte ratio (COP-NLR) in patients with esophageal squamous cell carcinoma (ESCC) were
investigated and compared. METHODS: This retrospective study included 375 patients who underwent
esophagectomy for ESCC. The cancer-specific survival (CSS) was calculated by the Kaplan-Meier method, and
the difference was assessed by the log-rank test. The GPS was calculated as follows: patients with elevated C-
reactive protein (N10 mg/l) and hypoalbuminemia (b35 g/l) were assigned to GPS2. Patients with one or no
abnormal value were assigned to GPS1 or GPS0, respectively. The COP-NLR was calculated as follows: patients
with elevated platelet count (N300 × 109/l) and neutrophil lymphocyte ratio (N3) were assigned to COP-NLR2.
Patients with one or no abnormal value were assigned to COP-NLR1 or COP-NLR0, respectively. RESULTS: The 5-
year CSS in patients with GPS0, 1, and 2 was 50.0%, 27.0%, and 12.5%, respectively (P b .001). The 5-year CSS in
patients with COP-NLR0, 1, and 2 was 51.8%, 27.0%, and 11.6%, respectively (P b .001). Multivariate analysis
showed that both GPS (P = .003) and COP-NLR (P = .003) were significant predictors in such patients. In addition,
our study demonstrated a similar hazard ratio (HR) between COP-NLR and GPS (HR = 1.394 vs HR = 1.367).
CONCLUSIONS: COP-NLR is an independent predictive factor in patients with ESCC. We conclude that COP-NLR
predicts survival in ESCC similar to GPS.
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Esophageal cancer (EC) is the eighth most common cancer worldwide
and the sixth leading cause of death from cancer [1]. Squamous cell
carcinoma (SCC) comprises about 80% of all ECs worldwide [2]. In
China, SCC is the most common pathologic type of ECs, in contrast
to the predominance of adenocarcinoma in the Western countries
[3,4]. There are important biologic differences between China and
Western countries regarding ECs; therefore, a prognostic study that
takes into account SCC in China is necessary.
Recently, systemic inflammatory response plays an important role
in the progression of cancer [5,6]. Previous studies have shown that
serum C-reactive protein (CRP) influenced the prognosis in patients
with gastrointestinal cancers [7]. Moreover, the Glasgow prognosticscore (GPS) combines serum CRP and hypoalbuminemia and has
been demonstrated to be a predictive factor in various cancers,
including ECs [8–10]. In addition, there is an increasing evidence
Table 1. The Characteristics of the 375 SCCE Patients Grouped by GPS
GPS0 (n) GPS1 (n) GPS2 (n) P Value
Age (years) .697
≤60 125 63 26
N60 87 52 22
Gender .245
Female 32 14 3
Male 180 101 45
Tumor length (cm) b .001
≤3 71 25 3
N3 141 90 45
Tumor location .193
Upper 9 7 4
Middle 93 61 26
Lower 110 47 18
Vessel involvement .101
Negative 183 90 37
Positive 29 25 11
Perineural invasion .226
Negative 177 92 35
Positive 35 23 13
Differentiation .273
Well 32 13 7
Moderate 144 75 27
Poor 36 27 14
Depth of invasion b .001
T1 49 13 1
T2 41 17 4
T3 108 67 35
T4 14 18 8
Nodal metastasis b .001
Negative 128 56 15
Positive 84 59 33
Translational Oncology Vol. 7, No. 5, 2014 COP-NLR Is a Predictive Factor in ESCC Patients Feng et al. 633that platelet count and neutrophil lymphocyte ratio (NLR) can be
used for prognostication in several cancers [11,12]. Recently, Ishizuka
et al. [13] evaluated a novel inflammation-based prognostic system,
termed as the combination of platelet count and NLR (COP-NLR).
They demonstrated that COP-NLR is a useful predictor of
postoperative survival in patients with colorectal cancer [13].
However, to the best of our knowledge, no studies regarding
COP-NLR in patients with EC are available. Therefore, the aim of
this study was to investigate and compare the prognostic values of
COP-NLR and GPS in patients with esophageal squamous cell
carcinoma (ESCC).
Methods
Patients
From January 2006 to December 2008, a retrospective analysis was
conducted in 375 patients with ESCC who underwent curative
esophagectomy at Zhejiang Cancer Hospital. All of the patients
included in the analysis fit the following criteria: 1) ESCC confirmed
by histopathology, 2) surgery with curative esophagectomy, 3) at least
six lymph nodes were examined for pathologic diagnosis, and 4)
surgery was neither preceded nor followed by adjuvant chemotherapy
and/or radiotherapy.
On the basis of the medical records, the following data were
collected for each patient: age, gender, laboratory examination,
differentiation, tumor length and location, depth of invasion, nodal
metastasis, and other miscellaneous characteristics. Ethical approval
was obtained from the Ethical Committees of Zhejiang Cancer
Hospital. All of the patients included in the study were staged
according to the seventh edition of the American Joint Committee on
Cancer Cancer Staging Manual [14].
In our institute, patients were followed up in the outpatient
department. X-ray or computed tomography of the chest was performed
during the follow-up. As this study described the prognosis of patients
with ESCC, therefore, a cancer-specific survival (CSS) analysis would be
more appropriate. Therefore, the CSS was ascertained in this study. The
last follow-up time was November 2011.
GPS and COP-NLR Evaluation
Routine laboratory measurements including the serum levels of CRP,
albumin, and blood cell counts were extracted in a retrospective fashion
from the medical records. GPS was calculated as follows: patients with
elevated CRP (N10mg/l) and hypoalbuminemia (b35 g/l) were assigned
to GPS2. Patients with one or no abnormal value were assigned to GPS1
or GPS0, respectively [8]. COP-NLR was calculated as follows: patients
with elevated platelet count level (N300 × 109/l) and NLR (N3) were
assigned to COP-NLR2. Patients with one or no abnormal value were
assigned to COP-NLR1 or COP-NLR0, respectively [13].
Statistical Analysis
Statistical evaluation was conducted with SPSS 17.0 (Chicago, IL).
The Pearson Chi-squared test was used to determine the significance
of differences. Correlation analysis was performed by Pearson and
Spearman correlation analyses. CSS was calculated by the Kaplan-
Meier method, and the difference was assessed by the log-rank test. A
univariate analysis was used to examine the association between
various prognostic predictors and CSS. Possible prognostic factors
associated with CSS on univariate analysis were considered in a
multivariable Cox proportional hazards regression analysis with the
enter method. Moreover, the Akaike information criterion (AIC) andBayesian information criteria (BIC) were used to identify the
statistical model [15,16]. AIC was defined as AIC = −2log(maximum
likelihood) + 2 × (the number of parameters in the model). BIC was
defined as BIC = −2log(maximum likelihood) + (the number of
parameters in the model) × log(sample size). A smaller AIC or BIC
value indicates a more desirable model for predicting the outcome. A
P value less than .05 was considered to be statistically significant.
Results
Patient Characteristics
Among the 375 patients with ESCC, 49 (13.1%) were women
and 326 (86.9%) were men. The mean age was 59.1 ± 7.8 years,
with an age range from 36 to 80 years. All of the clinicopathologic
characteristics were comparable between patients grouped by GPS
and COP-NLR, as shown in Tables 1 and 2. There were significant
differences between the GPS and COP-NLR groups in tumor
length (P b .001), depth of invasion (P b .001), and nodal metastasis
(P b .001). In addition, an elevated COP-NLR was also associated
with higher differentiation (P = .006).
Cancer-Specific Survival
The 5-year CSS was 38.1% in our study. The 5-year CSS in
patients with GPS0, 1, and 2 was 50.0%, 27.0%, and 12.5%,
respectively (GPS0 vs GPS1, P b .001; GPS1 vs GPS2, P = .035;
Figure 1). The 5-year CSS in patients with COP-NLR0, 1, and 2 was
51.8%, 27.0%, and 11.6%, respectively (COP-NLR0 vs COP-
NLR1, P b .001; COP-NLR1 vs COP-NLR2, P = .005; Figure 2).
Prognostic Factors
By univariate analysis, we found that seven clinicopathologic
variables had significant associations with CSS (Table 3). Then, all of
Table 2. The Characteristics of the 375 SCCE Patients Grouped by COP-NLR
COP-NLR0 (n) COP-NLR1 (n) COP-NLR2 (n) P Value
Age (years) .576
≤60 107 83 24
N60 88 54 19
Gender .287
Female 30 13 6
Male 165 124 37
Tumor length (cm) b .001
≤3 74 21 4
N3 121 116 39
Tumor location .785
Upper 10 9 1
Middle 92 68 20
Lower 93 60 22
Vessel involvement .688
Negative 164 112 34
Positive 31 25 9
Perineural invasion .531
Negative 161 107 36
Positive 34 30 7
Differentiation .006
Well 23 24 5
Moderate 142 82 22
Poor 30 31 16
Depth of invasion b .001
T1 48 12 3
T2 38 19 5
T3 96 86 28
T4 13 20 7
Nodal metastasis b .001
Negative 119 68 12
Positive 76 69 31
Figure 2. The 5-year CSS in patients with COP-NLR0, 1, and 2 was
51.8%, 27.0%, and 11.6%, respectively (COP-NLR0 vs COP-NLR1,
P b .001; COP-NLR1 vs COP-NLR2, P = .005).
Table 3. Univariate Analyses in Patients with ESCC
5-Year CSS (%) Chi-Square P Value HR (95% CI) P Value
Age (years) 0.074 .785 .787
≤60 38.3 1.000
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Cox proportional hazards model. In that model, we demonstrated
that both the GPS (P = .003) and the COP-NLR (P = .003) were
significant independent predictors of CSS (Table 4). In addition, our
study showed a similar hazard ratio (HR) between COP-NLR and
GPS (HR = 1.394 vs HR = 1.367).Figure 1. The 5-year CSS in patients with GPS0, 1, and 2 was
50.0%, 27.0%, and 12.5%, respectively (GPS0 vs GPS1, P b .001;
GPS1 vs GPS2, P = .035).Correlation Analysis
There were significant positive correlations between COP-NLR and
GPS (r = 0.494, P b .001). Our results showed significant negative
correlations between CRP and albumin (r = −0.300, P b .001;N60 37.9 1.036 (0.799-1.344)
Gender 0.761 .383 .389
Female 44.9 1.000
Male 37.1 1.193 (0.799-1.782)
Tumor length (cm) 16.001 b .001 b .001
≤3 53.5 1.000
N3 32.6 1.903 (1.376-2.632)
Tumor location 0.327 .568 .572
Upper/middle 40.0 1.000
Lower 36.0 1.077 (0.833-1.394)
Vessel involvement 11.874 .001 .001
Negative 41.6 1.000
Positive 21.5 1.709 (1.251-2.334)
Perineural invasion 6.453 .011 .013
Negative 41.4 1.000
Positive 25.4 1.479 (1.088-2.011)
Differentiation 3.777 .052 .055
Well/moderate 39.2 1.000
Poor 32.9 1.355 (0.993-1.850)
Depth of invasion 27.016 b .001 b .001
T1-2 58.2 1.000
T3-4 28.5 2.216 (1.623-3.024)
Nodal metastasis 60.200 b .001 b .001
Negative 54.8 1.000
Positive 19.3 2.735 (2.094-3.573)
GPS 51.088 b .001 b .001
0 50.0 1.000
1 27.0 2.075 (1.556-2.768)
2 12.5 3.107 (2.166-4.456)
COP-NLR 46.603 b .001 b .001
0 51.8 1.000
1 27.0 1.909 (1.439-2.532)
2 11.6 3.261 (2.230-4.767)
Table 4. Multivariate Analyses in Patients with ESCC
HR (95% CI) P Value
Tumor length (N3 cm vs ≤3 cm) 1.033 (0.716-1.490) .862
Vessel involvement (positive vs negative) 1.035 (0.742-1.442) .841
Perineural invasion (positive vs negative) 1.128 (0.821-1.550) .458
Depth of invasion (T3-4a vs T1-2) 1.459 (1.018-2.091) .040
Nodal metastasis (positive vs negative) 2.109 (1.567-2.837) b .001
GPS (1-2 vs 0) 1.367 (1.114-1.677) .003
COP-NLR (1-2 vs 0) 1.394 (1.120-1.735) .003
Figure 3. Negative correlations between CRP and albumin (A), NL
correlations between CRP and NLR (B) and CRP and platelet count (
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platelet count and albumin (r = −0.210, P b .001; Figure 3F). There
were significant positive correlations between CRP and NLR (r = 0.157,
P = .002; Figure 3B) and CRP and platelet count (r = 0.138, P = .007;
Figure 3C). However, there were no correlation between NLR and
platelet count (r = 0.079, P = .125; Figure 3D).
AIC and BIC Analyses
AIC and BIC values were calculated by using logistic regression
according to the survival status of patients when the follow-up was
over. The AIC and BIC values were similar between COP-NLR andR and albumin (E), and platelet count and albumin (F). Positive
C). No correlation between NLR and platelet count (D).
Table 5. AIC and BIC Analyses in Patients with ESCC
AIC BIC −2Log(Maximum Likelihood)
GPS 472.120 487.808 464.120
COP-NLR 468.824 484.532 460.824
636 COP-NLR Is a Predictive Factor in ESCC Patients Feng et al. Translational Oncology Vol. 7, No. 5, 2014GPS, indicating that COP-NLR predicts survival in ESCC similar to
GPS (Table 5).
Discussion
There is strong linkage between inflammation and cancer [5,6]. In our
study, we analyze the potential prognostic values of COP-NLR and
GPS in ESCC patients without adjuvant chemoradiotherapy mainly
because chemotherapy or radiation will have an important impact on
the systemic inflammation. To the best of our knowledge, this is the first
study to show COP-NLR as an independent prognostic factor in
patients with ESCC. Our study showed that both GPS (P = .003) and
COP-NLR (P = .003) were significantly associated with CSS in
multivariate analysis. We conclude that COP-NLR is an independent
predictive factor in patients with ESCC, and it predicts survival similar
to GPS.
There are now a number of well-established systemic inflammation-
based prognostic indexes for patients with EC. In particular, theGPS has
been well validated. Several previous studies have shown that GPS is
associated with survival in various cancers, including ECs [8–10]. Our
study showed that GPS was associated with tumor size, depth of
invasion, and nodal metastasis. This observation is in line with data from
Vashist et al. [8] but is contrary to the result of Kobayashi et al. [9], who
suggested that GPS has no significant correlation with the
above clinicopathologic factors. Moreover, our study demonstrated
that COP-NLR is an independent predictive factor in patients with
ESCC, and the result was consistent with previous studies [8,9].
However, some of the previous reports using the GPS had several
problems [17–19]. Therefore, the GPS may be considered insufficient
for prognostication.
There is an increasing evidence that platelet count and NLR can
be used for prognostication in patients with several types of cancer
[11,12]. Recently, Ishizuka et al. [13] showed that COP-NLR is
considered to be a useful predictor of postoperative survival in
patients with colorectal cancer. They showed that COP-NLR is
easy to measure routinely because of its low cost and convenience
[13]. Therefore, we conducted a study to determine whether COP-
NLR is useful for predicting long-term survival in patients with
ESCC. In our study, we demonstrated that COP-NLR (P = .003)
was significantly associated with CSS. Moreover, our study showed
a similar HR between COP-NLR and GPS. In addition, the
AIC and BIC values were similar between COP-NLR and GPS,
indicating that COP-NLR predicts survival in ESCC similar
to GPS.
The potential limitations of the present study include the use of a
retrospective analysis and the short duration of the mean follow-up
duration. In addition, we excluded patients who had adjuvant
chemotherapy and/or radiotherapy, which may have influenced our
analysis. Furthermore, AIC and BIC values were not correct
if follow-up differed between patients, and the results of the
study should therefore be regarded with caution. Thus, larger
prospective studies will need to be performed to confirm these
preliminary results.Conclusion
In summary, our study showed that both GPS and COP-NLR are
associated with tumor progression and can be considered as
independent markers in patients with ESCC. We conclude that
COP-NLR predicts survival in ESCC similar to GPS. However,
larger prospective studies will need to be performed to confirm these
preliminary results.
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